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Abstract 
Little is known about the S100B+ lymphocytes, which are unique human peripheral 
blood lymphocytes (PBL) containing the S100B protein. It has recently been shown that 
S100B is released from various types of S100B+ cells and exhibits varied cytokine-like 
activities. In this study, we precisely characterized the S100B+ lymphocytes of healthy 
adults with respect to the proportion in the whole PBL, immunophenotypes, function, 
and their S100B mRNA expression and also evaluated their S100B-releasing activity 
upon stimulation. S100B+ lymphocytes were detected in all individuals examined, and 
the proportion of S100B+ lymphocytes in the whole PBL ranged from 0.42 to 16.15% 
(mean 4.21%). In addition, two subtypes of S100B+ lymphocytes, a CTL subtype (CD3+ 
CD8+ CD16-) and a NK subtype (CD3- CD8- CD16+) were detected. The majority of the 
CTL subtype of S100B+ lymphocytes expressed the αβ-T cell receptor. Surprisingly, 
S100B mRNA was detected not only in S100B+ lymphocytes, but also in every S100B- 
lymphocytes, although the expression levels of S100B mRNA in S100B- lymphocytes 
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were much lower than those of S100B+ lymphocytes. The CTL subtype of S100B+ 
lymphocytes exhibited blastic morphological changes, proliferated and released S100B 
upon stimulation with PHA. The NK subtype of S100B+ lymphocytes exhibited 
morphological NK activity when co-cultivated with NK-sensitive target, K-562 cells. 
Thus, the CTL subtype S100B+ lymphocytes exhibit the biological characteristics of T 
cells, while the NK subtype S100B+ lymphocytes exhibit the characteristics of NK cells. 
These results suggest that S100B+ lymphocytes are a particular subtype of cytotoxic 
lymphocytes that play a unique role in anti-tumor immunity. 
 
Key words: S100B, peripheral blood, cytotoxic T cells, NK cells,  
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Introduction 
The S100 protein belongs to the EF-hand type calcium binding protein family, 
which includes calmodulin and the myosin light chain. S100 protein is involved in the 
Ca2+-dependent regulation of a variety of intracellular activities, such as protein 
phosphorylation, enzyme activities, cell proliferation and differentiation, the dynamics 
of cytoskeleton constituents, the structural organization of membranes, intracellular 
Ca2+ homeostasis, inflammation, in the protection against oxidative cell damage, cell 
cycle progression and differentiation. The S100 protein family comprises 19 members, 
and is widely distributed among human tissues. Some S100 members are released or 
secreted into the extracellular space and thereby exert either trophic or toxic effects 
depending on their concentration, and thus can act as chemoattractants for leukocytes, 
modulate cell proliferation, or regulate macrophage activation (1-3). 
S100B is localized mainly in astrocytes, and Schwann cells of the nervous 
system (4). In addition, the S100B protein is detected in chondrocytes, melanocytes, and 
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fat cells (5), dendritic cells (including interdigitating cells and Langerhans cells), and 
some of the peripheral blood T cells and activated macrophages in the human 
hematopoietic system (6, 7). 
The intracellular functions of S100B include the regulation of calcium 
homeostasis and enzyme activity (8). In the nervous system, S100B is released by 
astrocytes and oligodendrocytes. Secreted S100B exerts paracrine effects on neurons 
and microglia, as well as autocrine effects on astrocytes (9). At the nanomolar level, 
extracellular S100B exerts a dual effect on neurons depending on its concentration, i.e., 
a pro-survival effect on neurons and stimulation of neurite outgrowth. In contrast, 
micromolar levels of extracellular S100B in vitro stimulate the expression of 
pro-inflammatory cytokines and induce apoptosis (10, 11). Furthermore, evidence has 
indicated that S100B interacts with the tumor suppressor p53 (12, 13). S100B 
overexpression can reduce p53 transcriptional activity by more than 50%. This effect is 
correlated with a decrease in p53 DNA binding activity and a reduction in the 
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accumulation of the MDM2 and p21 proteins (14).  
S100B protein was first detected in the protein extract of whole T lymphocytes 
by Kanamori and colleagues (15). The S100B+ lymphocyte subset was first identified 
by Takahashi and colleagues (16), and they reported that S100B+ lymphocytes comprise 
approximately 1-4% (mean 3.4%) of peripheral blood mononuclear cells, and a part of 
CD3+ CD8+ cytotoxic T cells. They subsequently reported that S100B+ lymphocytes are 
significantly decreased in the peripheral blood of patients with advanced cancer, 
comprising only 0.5% of the peripheral blood lymphocytes (PBL) (16-21). Cases of 
malignant proliferative disorders involving S100B+ lymphocytes have been reported by 
several authors (22-26), and it has also been reported that the neoplastic counterparts of 
S100B+ lymphocytes display NK activity, suggesting that S100B+ lymphocytes are a 
particular type of cytotoxic T cells exhibiting NK activity. These reports suggest that 
S100B+ lymphocytes play an important role in anti-tumor immunity. However, the 
physiological function of S100B+ lymphocytes has been poorly understood, and remains 
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to be elucidated.  
Recently, Steiner and colleagues analyzed the S100B+ lymphocytes in human 
peripheral blood (27). They reported that the S100B+ lymphocyte subset comprises two 
distinctive lymphocyte subtypes, a S100B+ CD3+ CD8+ T lymphocyte subtype and a 
CD3- CD8- CD56+ NK subtype, and that the T subtype of S100B+ lymphocytes secrete 
S100B upon stimulation with an anti-CD3 antibody or phytohemagglutinin (PHA). 
Furthermore, high concentrations (μg/ml levels) of recombinant human S100B triggered 
the upregulation of CD11b and membrane shedding of CD62L in granulocytes and 
monocytes. These findings indicate that S100B might function as an interface to 
immunological processes, distinct from the known cytokine- and chemokine-mediated 
pathways. Moreover, Steiner and colleagues reported that S100B+ NK cells are 
increased in schizophrenia patients, and they may be linked with stress axis activation 
(28). These findings suggest that S100B+ lymphocytes play significant roles not only in 
anti-tumor immunity, but also in the regulation of inflammatory reactions and certain 
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physiological processes. 
In this study, we attempted to precisely characterize the S100B+ lymphocytes in 
healthy adult individuals with respect to the proportion, immunophenotypes, responses 
for T cells mitogen, the morphological response to NK-sensitive or –resistant target 
cells, and their S100B mRNA expression. We also attempted to confirm the release of 
S100B by S100B+ lymphocytes after stimulation with mitogen.  
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Materials and Methods 
Antibodies 
Table 1 summarizes the specific primary and secondary antibodies used in this 
study. 
 
Cell lines and cell culture 
The cells were cultured in RPMI 1640 or DMEM medium containing 10% fetal 
calf serum (FCS), penicillin (100 units/ml), streptomycin (100 μg/ml) and kanamycin 
(60 μg/ml). The human acute leukemia Jurkat cells (a T cell leukemia cell line), HUT78 
(human Sezary syndrome cell line) and Daudi (human Burkitt’s lymphoma cell line) 
cells were cultured in RPMI 1640 medium. A2058 (human melanoma cell line) and 
HeLa (human cervical adenocarcinoma cell line) cells were cultured in DMEM.  
 
Preparation of peripheral blood lymphocytes 
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Peripheral blood mononuclear cells were obtained from the heparinized 
peripheral venous blood of 30 healthy adults [14 male, 16 female, ages ranging from 22 
to 61 (mean 38.6, median 31) years old]. Mononuclear cells were collected by density 
gradient centrifugation using LSM® Lymphocyte Separation Medium (MP Biomedicals 
LLC, Irvine CA, USA), and were suspended in RPMI-1640 medium. The mononuclear 
cell suspensions were incubated in culture dishes that had been treated with autologous 
human serum for 15 min at 37oC. After removal of the adherent cells (monocytes), 
non-adherent cells were collected, washed, re-suspended in phosphate buffered saline 
(PBS), and examined as PBL. 
 
Flow cytometric analysis and cell sorting 
The PBL were re-suspended at a concentration of 1 x 106 /ml cells in PBS. First, 
the PBL were stained with various antibodies against lymphocyte cell surface molecules. 
When performing three-color staining, the PBL were incubated with 20 μl/ml 
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biotin-labeled mouse monoclonal antibodies against CD3 or CD8 or CD16 for 30 min 
on ice. The PBL were washed with PBS, and incubated with 20 μl streptavidin PerCP 
and PE-labeled mouse monoclonal antibodies against each of the cell surface molecules, 
as listed in Table 1, for 30 min on ice. When performing two-color staining, the PBL 
were incubated with 1 ml of PBS containing appropriately diluted PE-labeled mouse 
monoclonal antibodies for 30 min on ice. The PBL were then washed with PBS and 
treated with IntraPrep Permeabilization Reagent (Beckman coulter Corp., Miami, FL, 
USA) according to the manufacturer’s instructions, for detection of the intracellular 
protein S100B. After washing, the PBL were re-suspended in 1 ml of PBL containing an 
appropriate amount of rabbit anti-S100B antibody for 30 min on ice. After washing, the 
PBL were re-suspended in 1 ml of PBS containing FITC-conjugated goat anti-rabbit 
IgG diluted according to the manufacture’s instructions for 30 min on ice. After washing, 
the PBL were fixed with 4% paraformaldehyde in PBS. 
The two- or three-color flow cytometric analyses were performed on a 
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FACSCalibur instrument (BD Biosciences, San Jose, CA, USA). Acquisition was done 
until 5000 lymphocytes were detected. The data analyses were performed using the Cell 
Quest™ Pro Software (BD Biosciences), which employs Forward Scatter (FSC)/Side 
Scatter (SSC) lymphocyte gating.  
Furthermore, the PBL were sorted into the S100B- CD3+ CD8+ CD16- (CTL), 
S100B+ CTL subtype, S100B- CD3- CD16+ (NK cells), S100B+ NK subtype, CD4+ Th 
cells, and CD19+ B cells, using the FACSAria instrument (BD Biosciences) and FACS 
Diva Software program (V5.0.3) (BD Biosciences). 
 
RNA extraction and real-time RT-PCR 
The S100B mRNA expression in cells, including cell lines, whole PBL, and 
sorted lymphocytes (S100B- CTL, S100B+ CTL subtype, S100B- NK cells, S100+ NK 
subtype, CD4+ Th cells, CD19+ B cells), was examined. Total RNA from cell lines and 
whole PBL were isolated with the RNeasy Mini Kit (QIAGEN, Hilden, Germany), and 
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total RNA from sorted lymphocytes were isolated with a RNeasy FFPE Kit (QIAGEN), 
according to the manufacturer’s instructions. The expression levels of S100B 
transcription were measured relative to the expression of β-actin using an ABI Step 
OneTM and Step One PlusTM Real Time PCR System (Applied Biosystems, Foster City, 
CA, USA). All reactions were performed using a One Step SYBR® Prime Script® PLUS 
RT-PCR Kit (Perfect Real Time) (Takara Bio Inc., Shiga, Japan). The expression levels 
are given as dCT, which were calculated by subtracting the cycle threshold value (the 
cycle number at which the message is first detected) for β-actin from the cycle threshold 
value for each transcript. Lower dCT values indicate higher RNA levels. As the cycle 
thresholds were in the exponential phase of amplification, a 1 dCT difference is 
equivalent to a 2-fold change in the mRNA levels (29). All reactions were carried out in 
triplicate. The primer sequences used are listed in Table 2. To confirm that the PCR 
products were of a specific sequence, they were separated by 2% agarose gel 
electrophoresis, and bands were visualized under ultraviolet radiation after staining with 
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ethidium bromide. The detected bands were excised from the agarose gels, and purified 
using the GENE CLEAN Kit (MP-Biomedicals) according to the manufacturer’s 
instructions. Then, the purified DNA was sequenced using an ABI 3130xl Genetic 
Analyzer (Applied Biosystems). 
 
Stimulation with T cell mitogen and quantification of S100B in the culture 
supernatants of lymphocytes 
Fresh PBL (1 x 106 cells/ml) were suspended in RPMI 1640 medium and 10 
μg/ml of PHA (Sigma Aldrich, St. Louis, MO, USA) or were left untreated (without 
mitogens) for 4 days at 37oC in 5% CO2 and humidified air. Thereafter, the cells and the 
supernatants were harvested and analyzed at different time points. The cells were 
stained with S100B and various antibodies for lymphocyte cell surface molecules, as 
described above. Then, they were analyzed by the FACSCalibur instrument. The 
supernatants were evaluated with a Human S100B ELISA Kit (Millipore Corporation, 
 16
Billerica, MA, USA) according to the instructions provided by the manufacturer. The 
amount of S100B protein was corrected after setting the value of the RPMI 1640 
medium as 0 pg/ml. Measurements were performed in duplicate. In addition, the cells 
cultured for 72 hours were smeared with Cytocentrifuge (Sakura Finetek, Tokyo, 
Japan).  
 
Co-cultivation of PBL with K562 cells and BALL-1 cells 
Fresh PBL (n = 1 x 106 cells) were co-cultivated with NK-sensitive K562 cells 
or NK-resistant BALL-1 cells (n = 1 x 105 cells) in 2.0 ml of the RPMI 1640 medium 
for 3 hours at 37oC in 5% CO2 and humidified air. These cells were then smeared with 
Cytocentrifuge.  
 
Cell smear preparation 
The cultured cells were smeared on Frontier slides (Matsunami Glass Ind., Ltd; 
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Osaka, Japan) with Cytocentrifuge, and immediately fixed with 4% paraformaldehyde 
for 30 min. The cell smears were washed with PBS and air-dried. The cell smears were 
examined by two-color immunofluorescence staining, and then were stained with 
May-Grünwald-Giemsa stain. 
 
Two-color immunofluorescence staining 
The cell smears were treated with 3% H2O2 and immersed in 10% normal goat 
serum. They were then incubated with rabbit anti-S100B at 4oC overnight. After 
washing them with PBS, the cell smears were stained with FITC-conjugated goat 
anti-rabbit IgG at a dilution of 1:500, and a PE-conjugated mouse monoclonal antibody 
against CD3, CD8 or CD16 at a dilution of 1:250. The cell smears were observed with a 
LSM510 confocal laser scanning microscope (Carl Zeiss). 
 
Statistical analysis 
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The statistical analyses were performed using the SPSW software program 
(version 18.0; SPSS Inc.).  
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Results 
Immunophenotype of S100B+ lymphocytes 
S100B+ lymphocytes expressed CD3, CD8, CD16, CD56, CD161, CD244 
(2B4) and CD314 (NKG2D) (Figure 1A-F), but did not express CD4, CD25, CD19, or 
HLA-DR (Figure 1G-J). Although CD314 was expressed on all S100B+ lymphocytes, 
CD3, CD8, CD16, CD56, CD161, and CD244 were expressed on only some of the 
S100B+ lymphocytes. The three-color flow cytometric analysis indicated that two 
distinct subtypes of S100B+ lymphocytes, the CTL subtype (CD3+ CD8+ CD16-) and the 
NK subtype (CD3- CD8- CD16+), were present in the peripheral blood. Almost all cells 
of the NK subtype of S100B+ lymphocytes expressed CD56. The majority of the CTL 
subtype of S100B+ lymphocytes expressed the αβ-T cell receptor (TCR) (Figure 2A). A 
small number of the CTL subtype of S100B+ lymphocytes (around 5-10%) expressing 
the γδ-TCR were detected (Figure 2B). These cells strongly expressed CD3 and weakly 
expressed CD16. Such cells could not be detected as a distinct cell population in most 
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of individuals examined. The NK subtype of S100B+ lymphocytes did not express the 
αβ-TCR or γδ-TCR. There were no S100B+ lymphocytes that expressed Vα24-TCR, 
which is known to be expressed on NKT cells (Figure 2C). 
 
The proportion of S100B+ lymphocytes in the whole PBL of healthy individuals 
The proportion of S100B+ lymphocytes in the whole PBL varied considerably 
among the healthy individuals examined (Table 3). S100B+ lymphocytes were detected 
in all individuals examined, but the proportion of S100B+ lymphocytes in the whole 
PBL population ranged from 0.42 to 16.15% (mean 4.21%). There were no significant 
differences between males and females (t-test, p = 0.578) (Figure 3A). In contrast, the 
mean of the older group (> 32 years old) was 3.01%, while that of the younger group (< 
32 years old) was 5.26%. Although this difference was statistically not significant (t-test, 
p = 0.077) (Figure 3B), it was suggested that there is a trend for the proportion to 
decrease with age. 
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Moreover, the average proportion of the CTL subtype of S100B+ lymphocytes 
in the younger group was 3.59%, while that of the older group was only 1.18%, and this 
difference was statistically significant (t-test, p = 0.012). In addition, almost all S100B+ 
lymphocytes in the younger group were of the CTL subtype. These findings indicate 
that there is a tendency for the proportion of the CTL subtype of S100B+ lymphocytes to 
decrease with age, and suggested that the subpopulation of the NK subtype of S100B+ 
lymphocytes increases with age although this difference was statistically not significant 
(t-test, p = 0.406) (Figure 3C). In contrast, there were no significant differences in the 
proportions of ordinary CTL and NK cells between the younger and older groups 
(Figure 3D). 
 
S100B mRNA expression 
Surprisingly, the expression of S100B mRNA was detected not only in S100B+ 
lymphocytes, but also in S100B- lymphocytes, such as CD4+ T cells and B cells, 
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although the expression levels of these S100B- populations were much lower than those 
of the S100B+ lymphocyte populations (lower than one-hundredth) (Figure 4A). The 
transcription of S100B was confirmed by a sequential analysis. The mRNA expression 
of S100B was also detected in all cell lines examined, including both S100B+ and 
S100B- cell lines, although the expression level of S100B mRNA in the S100B+ 
melanoma cell line (A2058) was much higher than that of the S100B- cell lines.  
In contrast, there were no significant differences in the p53 mRNA expression 
levels among the PBL subpopulations (Figure 4B), and there was no definite correlation 
between the S100B mRNA and p53 mRNA expression levels, although it has been 
demonstrated that S100B is functionally associated with p53. 
 
Biological activities of S100B+ lymphocytes 
(1) Stimulation with the T cell mitogen, PHA 
The expression of S100B protein was investigated after stimulation of PBL 
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with PHA. Non-stimulated PBL were used as controls. The number of PBL increased 
approximately two-fold in 96 hours upon stimulation with PHA. The majority of the 
PBL that were stimulated with PHA for 72 hours displayed marked blastic 
morphological changes. The CTL subtype of S100B+ lymphocytes, as well as ordinary 
S100B- T cells, displayed these blastic morphological changes, while the NK subtype of 
S100B+ lymphocytes and ordinary S100B- NK cells did not. The CTL subtype of 
S100B+ lymphocytes increased in number upon PHA stimulation, whereas the 
population of NK subtype of S100B+ lymphocytes decreased (Figure 5A). These 
findings indicate the distinctive T cell nature of the CTL subtype of S100B+ 
lymphocytes. The CD4+ lymphocytes and CD19+ lymphocytes were not converted to be 
positive for S100B upon PHA stimulation.  
Furthermore, we examined whether or not the CTL subtype of S100B+ 
lymphocytes released S100B into the culture medium upon PHA stimulation. S100B 
was not detected in the culture supernatant of control PBL cultured without PHA. In 
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contrast, S100B was detected in the culture supernatant of PBL culture with PHA, and 
the concentration continuously increased during the culture (Figure 5B). These findings 
indicate that the CTL subtype of S100B+ lymphocytes release S100B upon stimulation 
with PHA.  
 
(2) Co-cultivation of PBL with NK-sensitive K-562 cells or NK-resistant BALL-1 cells 
No method is currently available for purifying living NK subtype of S100B+ 
lymphocytes to evaluate their NK activity directly. Therefore, we attempted to indirectly 
evaluate their NK activity. Briefly, we examined whether or not the NK subtype of 
S100B+ lymphocytes attached specifically to NK-sensitive K-562 cells upon 
co-cultivation. We regarded only flattened cells adhering to K-562 cells as lymphocytes 
with NK activity, and regarded adherent lymphocytes without such morphological 
changes as accidentally adjoining cells. Two-color immunofluorescence staining 
indicated that both S100B- CD16+ NK cells (ordinary NK cells; red) and S100B+ CD16+ 
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cells (NK subtype S100B+ lymphocytes; yellow) adhered to NK-sensitive K562 cells 
upon co-cultivation. These cells intimately attached to K-562 cells and became flattened 
in shape (Figures 6A and B). In contrast, none of the lymphocytes adhered to the 
NK-resistant BALL-1 cells (Figure 6C). These findings strongly suggest that the NK 
subtype of S100B+ lymphocytes possess NK activity.  
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Discussion 
In the present study, we examined the immunophenotype, functional 
characteristics and mRNA expression of the S100B+ lymphocytes in human peripheral 
blood. We found that S100B+ lymphocytes are present in the peripheral blood of all 
individuals examined as a distinct population of PBL (0.42-16.15%, mean 4.21%). 
There was no statistically significant difference in the average proportion of S100B+ 
lymphocytes between males and females. As shown in this study, the average proportion 
of S100B+ lymphocytes to the whole PBL population of the older individuals (> 32 
years old) tended to be lower than that of the younger individuals (< 32 years old), 
although the difference was not statistically significant. These findings imply that 
S100B+ lymphocytes play a crucial role in the immune system. 
A flow cytometric analysis indicated that S100B+ lymphocytes consist of two 
distinctive subtypes, the CTL subtype (CD3+ CD8+ CD16-) of S100B+ lymphocytes and 
the NK subtype (CD3- CD8- CD16+) of S100B+ lymphocytes. The present study 
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indicated that the proportion of NK subtype of S100B+ lymphocytes to the whole 
population of S100B+ lymphocytes of the older group tended to be higher than that of 
the younger group. These findings suggest that the proportion of the NK subtype of 
S100B+ lymphocytes to the whole population of S100B+ lymphocytes tended to 
increase, and conversely, that the subpopulation of the CTL subtype of S100B+ 
lymphocytes tended to decrease with age. In contrast to the S100B+ lymphocytes, such a 
tendency was not observed in the ordinary CTL and NK subtypes in this study. 
Previously, Xu and colleagues reported that there were significant differences in the 
proportion of ordinary CTL and NK subpopulations between an aged group (>70 years 
old) and a young group (18-25 years old) (30). Specifically, they demonstrated that 
there were fewer CD3+ CD8+ CTL and more CD16+ NK cells in the peripheral blood of 
the aged subjects compared with the younger group. In the present study, however, we 
detected such differences in the S100B+ lymphocyte subtypes, but not in the ordinary 
lymphocyte subtypes. This discrepancy may be due to the fact that the older group in 
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our study (32-60 years old) was much younger than the aged group of the study reported 
by Xu and colleagues (over 70 years old). It is possible that the S100B+ lymphocyte 
subtypes are more sensitive to age than ordinary S100B- lymphocyte subtypes. 
The S100B+ lymphocyte population was discovered over 30 years ago. In the 
early reports, only the CTL subtype of S100B+ lymphocytes (CD3+ CD8+) was 
described (16-21). Subsequently, several cases of neoplastic disorders involving S100B+ 
lymphocytes have been reported (22-24, 26). All of these cases were characterized by an 
extensive leukemic increase of CD3+ S100B+ T cells and an aggressive clinical course. 
Interestingly, in some of these cases, the neoplastic counterparts of CD3+ S100B+ T 
cells were reported to simultaneously express NK cell antigens, including CD16, CD11b, 
CD11c and/or CD56, although such lymphocytes are not present in the peripheral blood 
(16, 25). A previous study by Steiner and colleagues and our present study indicate the 
presence of a NK subtype of S100B+ lymphocytes in the peripheral blood of healthy 
individuals (27). These findings imply that the NK subtype of S100B+ lymphocytes is 
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ontogenically closely related to the CTL subtype of S100B+ lymphocytes. 
In addition, both the CTL and NK subtypes of S100B+ lymphocytes express 
CD161, 2B4 (CD244) and NKG2D (CD314). These molecules are known to be 
expressed on the surface of ordinary NK cells and CD8+ T cells. CD161 is homologous 
to the Ca2+-dependent lectin-like receptors. Although the function of CD161 has not 
been fully elucidated, it has been suggested that CD161 serves as a specific receptor for 
some NK cell targets (31). The 2B4 protein is known to be expressed on cells mediating 
non-MHC-restricted cytotoxicity. It is a member of the CD2 receptor subfamily, which 
have both activating and inhibitory functions in NK cells (32, 33). NKG2D was 
reported to be expressed on effector cells involved in both innate and adaptive immune 
responses. NKG2D binds to the MICA and MICB (MHC class-I chain-related protein A 
and B) expressed on epithelial tumor cells (34, 35). Therefore, the expression of these 
molecules on S100B+ lymphocytes further suggests that S100B+ lymphocytes have a 
cytotoxic function. CTL and NK cells are known to use a combination of several 
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mechanisms to lyse different target cells. For example, they mediate Ca2+-dependent 
granule exocytosis and the release of cytotoxic proteins (perforin and granzyme) from 
intracytoplasmic granules; constitutively express or induce FasL expresson upon 
interaction with target cells, leading to the induction of Ca2+-independent, Fas-mediated 
apoptosis; and produce membrane-bound or secreted cytokines (36). It seems possible 
that the S100B protein in S100B+ lymphocytes may act as a calcium-binding protein 
involved in cytotoxicity. 
The present analysis of the TCR revealed that the majority of the CTL subtype 
S100B+ lymphocytes expressed αβ-TCR, while a small number of them (around 
5-10%) expressed the γδ-TCR. The function of this minor population should be 
examined in further investigations. In contrast to S100B+ lymphocytes, the NK subtype 
of S100B+ lymphocytes did not express αβ-TCR or γδ-TCR, similar to ordinary CTL 
and NK cells.  
The present finding that S100B+ lymphocytes do not express Vα24-TCR 
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indicates that S100B+ lymphocytes are different from NKT cells, because this molecule 
is reported to be expressed exclusively on NKT cells. NKT cells are a unique small 
subpopulation of lymphocytes (less than 0.1% of PBL) that represent a subset of mature 
T lymphocytes expressing the TCR as well as NK cell markers. NKT cells serve as a 
bridge between the innate and adaptive immune systems (37, 38).  
Furthermore, the present study indicated that the CTL subtype of S100B+ 
lymphocytes, but not the NK subtype of S100B+ lymphocytes, displayed a proliferative 
response to PHA similar to that of ordinary T cells, and that the NK subtype of S100B+ 
lymphocytes attached to NK-sensitive targets, such as K-562 cells, upon co-cultivation 
as did the ordinary NK cells. These findings indicate that there is no significant 
difference between the CTL subtype of S100B+ lymphocytes and ordinary CTL or 
between the NK subtype of S100B+ lymphocytes and ordinary NK cells, except for the 
expression of the S100B protein in S100B+ lymphocytes. These results lend support to 
the finding by Steiner and colleagues that the functional characterization of S100B 
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positive and S100B negative T lymphocyte subsets showed that these cells are similar in 
their IFNγ and IL-2 production upon stimulation with PMA/ionomycin (27). 
Curiously, S100B mRNA were expressed in not only S100B+ lymphocytes, but 
also S100B- lymphocytes, including CD4+ T cells and even B cells, in this study, 
although the expression levels of S100B mRNA in S100B- lymphocytes were much 
lower (less than one-hundredth) than those of S100B+
 
lymphocytes. The presence of 
S100B mRNA in S100B- lymphocytes was confirmed by agarose gel electrophoresis 
and a sequence analysis. These results suggest that not only S100B+ lymphocytes, but 
also S100B- lymphocytes, have the ability to produce the S100B protein following 
exposure to certain stimuli. However, the CD4+ T cells and B cells did not express 
S100B upon stimulation with PHA in this study. Why CD4+ T cells and B cells do not 
produce the S100B protein, despite the presence of S100B mRNA, and the biological 
significance of such low levels of S100B mRNA in S100B- lymphocytes should be 
determined in further investigations.  
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It has recently been reported that S100B interacts with the tumor suppressor 
p53 (8,13), which plays a pivotal role in the maintenance and regulation of normal 
cellular functions, and its inactivation can affect cell cycle checkpoints, apoptosis, gene 
amplification, centrosome duplication, and ploidy (39). Specifically, S100B inhibits p53 
tetramer formation and p53 C-terminal phosphorylation mediated by protein kinase C, 
resulting in the inhibition of p53 DNA binding and transcriptional activity (14). Our 
present study, however, indicated that the expression levels of p53 mRNA are almost the 
same among the various PBL subpopulations in spite of the extensive differences in the 
expression levels of S100B mRNA among these subpopulations. These findings suggest 
that S100B is not directly involved in the inhibition of p53 gene transcription in S100B+ 
lymphocytes. 
We confirmed that PHA stimulation led to the extracellular release of S100B by 
S100B+ lymphocytes. Moreover, we found that the number CTL subtype S100B+ 
lymphocytes, as well as that of ordinary CTL, increased and exhibited blastic 
 34
morphological changes after PHA stimulation. In contrast, the proportions of whole NK 
cells and the NK subtype of S100B+ lymphocytes in the whole PBL decreased 96 hours 
after PHA stimulation, and these lymphocytes did not display the blastic morphological 
changes. Steiner and colleagues have recently reported the extracellular secretion of 
S100B by S100B+ lymphocytes upon stimulation with PHA or an anti-CD3 antibody 
(27). They also indicated that the number of S100B+ T cells decreased significantly after 
PHA or anti-CD3 antibody stimulation, and suggested that S100B+ T lymphocytes 
become negative for S100B after they release it. However, the present results do not 
support their view, because the numbers of both whole CTL and the CTL subtype of 
S100B+ lymphocytes increased after PHA stimulation. It seems likely that CTL subtype 
of S100B+ lymphocytes are continuously positive for S100B even after releasing 
S100B. 
It has been reported that extracellular S100B exerts a dual effect on neurons 
depending on its concentration, i.e., a pro-survival effect on neurons and stimulation of 
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neurite outgrowth at nanomolar levels and a toxic effect at micromolar levels (neuronal 
death via apoptosis) (11). If the S100B released from S100B+ T lymphocytes induces 
similar stimulatory biological effects on immune cells, S100B+ lymphocytes might play 
an important role in the host defense. Accordingly, Steiner and colleagues reported that 
S100B induces granulocytes and monocytes to express the adhesion molecule CD11b 
and leads to the membrane shedding of CD62L, resulting in the functional stimulation 
of granulocytes and monocytes (27).  
The receptor for advanced glycation end products (RAGE) is a multi-ligand 
receptor of the immunoglobulin superfamily and is involved in several diseases, such as 
complications of diabetes, cardiovascular diseases, Alzheimer’s disease, and cancer. 
RAGE has been identified as a cell surface receptor for S100B, and triggers cellular 
signaling (40). Akirav and colleagues reported that RAGE is expressed in both CD4+ 
and CD8+ T cells at similar levels. Moreover, they reported that the proportion of T cells 
expressing RAGE is increased when peripheral blood cells are cultured with an 
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Epstein-Barr virus peptide and S100B (41). These findings suggest that the S100B 
released from S100B+ lymphocytes induces the expression of RAGE in T cells, 
resulting in the activation of T cells.  
In order to clarify the biological significance of S100B in NK subtype of 
S100B+ lymphocytes, we examined whether or not the NK subtype of S100B+ 
lymphocytes released S100B into the culture medium upon co-cultivation with 
NK-sensitive K-562 cells.  But we failed to detect released S100B in the co-culture 
supernatant in this experiment (unpublished data). It remains unclear whether or not 
such an experiment is enough to activate NK-type of S100B+ lymphocytes. The 
biological significance of S100B remains to be determined. 
In conclusion, our study demonstrated the function and mRNA expression of 
the lymphocytes expressed S100B in the cytoplasm of human peripheral blood cells. We 
found that S100B+ lymphocytes are a particular subset of lymphocytes that differ from 
those known so far, and that they appear to have an important role in the immune 
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system. Further studies should be performed to address what function, they perform 
based on different lifestyle- and living environment-related factors, and under 
pathological conditions, such as autoimmune disease and cancer.  
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Tables 
Table 1. List of the antibodies used in this study 
Antibodies Clone Sources
Polyclonal Rabbit Anti-Human S100B A5110 Dako Cytomation
PE-Conjugated Monoclonal Mouse Anti-Human CD3 UCHT1 BD Pharmingen
PE-Conjugated Monoclonal Mouse Anti-Human CD4 RPA-T4 BD Pharmingen
PE-Conjugated Monoclonal Mouse Anti-Human CD244 2-69 BD Pharmingen
PE-Conjugated Monoclonal Mouse Anti-Human HLA-DR L243 BD Pharmingen
RPE-Conjugated Monoclonal Mouse Anti-Human CD8 DK25 Dako Cytomation
RPE-Conjugated Monoclonal Mouse Anti-Human CD16 DJ130c Dako Cytomation
RPE-Conjugated Monoclonal Mouse Anti-Human CD25 ACT-1 Dako Cytomation
RPE-Conjugated Monoclonal Mouse Anti-Human CD19 HD37 Dako Cytomation
Phycoerythin (PE) anti-human CD56 CMSSB eBioscience
Phycoerythin (PE) anti-human CD314/ NKG2D 1D11 eBioscience
Anti-Human CD19 APC HIB19 eBioscience
Phycoerythin (PE) anti-human αβTcR IP26 eBioscience
Phycoerythin (PE) anti-human γδTcR B1.1 eBioscience
PE-Conjugated Monoclonal Mouse Anti-Human CD161 191B8 IMMUNOTECH
RPE-Conjugated Monoclonal Mouse Anti-Human TCR Vα24 C15 Serotec Ltd.
FITC Goat Anti-Rabbit IgG(H+L) Conjugated ZYMED® Laboratories
Streptavidin PerCP BD Pharmingen
Biotin Mouse Anti-Human CD3 HIT3a BD Pharmingen
Biotin Mouse Anti-Human CD8 RPA-T8 BD Pharmingen
Biotin Mouse Anti-Human CD16 3G8 BD Pharmingen  
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Table 2. List of the primers used for real-time PCR. 
Sequence Product size Gene Bank Acc.
F CATCAACAATGAGCTTTCCCATTT
R GGCAGTAGTAACCATGGCAACAAAG
F ACTAAGCGAGCACTGCCCAAC
R CCTCATTCAGCTCTCGGAACATC
F TGGCACCCAGCACAATGAA
R CTAAGTCATAGTCCGCCTAGAAGCA
β-actin 186 NM_001101
Gene
S100B 145 NM_006272.2
p53 130 NM_000546
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Table 3. Proportion of S100B+ lymphocytes in the PBLs of healthy individuals. 
distribution mean median
Age (year) 22 - 61 38.63 31
Male / Female 14 / 16
CD3+ T-cells (%) 48.38 - 83.23 64.41 64.28
CD8+ T-cells (%) 11.76 - 42.73 27.24 27.61
NK-cells (%) 5.36 - 35.62 18.37 17.5
S100B+ lymphocytes (%) 0.42 – 16.15 4.21 3.1
CTL-subtype S100B+ lymphocytes (%) 0.16 - 11.22 2.6 1.97
NK-subtype S100B+ lymphocytes (%) 0.01 - 5.76 1.48 0.97  
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Figure legends 
Figure 1. Immunophenotyping of S100B+ lymphocytes by flow cytometry. The PBL of 
a healthy adult were stained for various lymphocyte surface markers and cytoplasmic 
S100B protein. A three-color flow cytometric analysis of the PBL for S100B/CD3/CD8 
(A), S100B/CD3/CD16 (B), S100B/CD56/CD16 (C), and a two-color analysis for 
S100B/CD161 (D), S100B/CD244 (E), S100B/CD314 (F), S100B/CD4 (G), 
S100B/CD25 (H), S100B/CD19 (I), and S100B/HLA-DR (J) were performed. 
A and B: There are two subtype of S100B+ lymphocytes, the S100B+ CD3+ CD8+ 
CD16- subtype (CTL subtype; red dots) and the S100B+ CD3- CD8- CD16+ subtype 
(NK subtype; blue dots). 
C: The NK subtype of S100B lymphocytes also express CD56. 
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Figure 2. T cell receptor (TCR) expression on S100B+ lymphocytes detected by flow 
cytometry. PBL of a healthy adult were stained for various TCR and S100B. A 
three-color flow cytometric analysis of the PBL for S100B/αβ-TCR/CD3 (A), 
S100B/αβ-TCR/CD8 (B), S100B/αβ-TCR/CD16 (C), S100B/γδ-TCR/CD3 (D), 
S100B/γδ-TCR/CD8 (E), and S100B/γδ-TCR/CD16 (F) was performed. A two-color 
flow cytometric analysis was performed for S100B and Vα24-TCR (G). 
A, B, C: S100B and αβ-TCR double positive lymphocytes are indicated by red blots, 
and S100B positive and αβ-TCR negative lymphocytes are indicated by blue blots. 
D, E, F: S100B and γδ-TCR double positive lymphocytes are indicated by red blots, and 
S100B positive and γδ-TCR negative lymphocytes are indicated by blue blots.  
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Figure 3. Comparison of the proportion of S100B+ lymphocytes to the whole PBL 
among healthy individuals (A-C). (A) A comparison of the younger group (< 32 years 
old) with the elder group (> 32 years old). (B) A comparison of males and females. (C) 
A comparison of the proportion of CTL subtype or NK subtype cells in the younger and 
older group. The proportion of the CTL subtype lymphocytes in the younger group was 
significantly higher than that of the older group (p < 0.05). (D) A comparison of the 
proportion of S100B- ordinary lymphocyte subpopulations (S100B- CD3+, S100B- CD8+, 
S100B- CD16+) to the whole PBL of the younger and older groups. 
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Figure 4. A comparison of the expression levels of S100B mRNA (A) and p53 mRNA 
(B) among the PBL subpopulations (S100B+ CTL subtype, S100B- CTL, S100B+; NK 
subtype, S100B- NK cells, CD4+ T cells, B cells) and the different cell lines [Jurkat (T 
cell), HUT78 (T cell), Daudi (B cell), HeLa (epithelial cell), A2058 (melanoma)] by 
real-time RT-PCR. The expression levels of S100B transcripts were measured relative to 
the expression of β-actin. Note that S100B+ cells exhibited high levels of S100B mRNA 
expression and that S100B- cells also exhibited low levels of S100B mRNA expression. 
There were no significant differences in the p53 mRNA levels among the PBL 
subpopulations.  
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Figure 5. Stimulation of cells with the T cell mitogen, PHA. Fresh PBL were cultured 
with PHA (10 μg/ml) or without PHA. 
A: Proportional changes in the CTL or NK subtype of S100B+ lymphocytes compared 
to the whole PBL cultured with or without PHA. ■: CTL subtype, ▲: NK subtype, ●: 
Whole S100B+ lymphocytes. The solid line indicates PHA stimulation, and the dashed 
line indicates cells cultured without PHA. Note that the proportion of the CTL subtype 
of S100B+ lymphocytes, but not the NK subtype, increased during stimulation with 
PHA. 
B: The concentration of S100B protein in the culture medium of PHA-stimulated or 
control PBL measured by an ELISA. The S100B protein accumulated in the culture 
medium during PHA stimulation. 
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Figure 6. The results of the morphological analysis of the NK subtype of S100B+ 
lymphocytes when they were co-cultivated with NK-sensitive K-562 cells (A, B) or 
NK-resistant BALL-1 cells (C) (original magnification x400). 
A: May-Grünwald-Giemsa staining. Note that some of the lymphocytes adhered to 
K-562 cells. 
B: The two-color immunofluorescence analysis of S100B (FITC) and CD16 (PE) 
expression. Note the flattened NK subtype of S100B+ lymphocyte (yellow) adhering to 
the K-562 cells. 
C: May-Grünwald-Giemsa staining. Note that none of the lymphocytes adhered to 
BALL-1 cells. 
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